Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06393400 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CHemotherapy And Stool Transplant in PDAC (CHASe-PDAC)

Study acronym: CHASe-PDAC
StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 25 words
    • Secondary endpoints: details revised at 2 of 5 entries
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 27, 2024 to Jan 8, 2025
    • Site details revised
    v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To confirm the safety of combining oral fecal microbiota transplantation (FMT) with gemcitabine and nab-paclitaxel chemotherapy as first line treatment in patients with unresectable or metastatic pancreatic ductal adenocarcinoma.
Trial Details
NCT Number NCT06393400
Lead Sponsor John Lenehan
Conditions
(from sponsor)		 Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma
Related terms Anophthalmia with pulmonary hypoplasia
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov